65,437 trials
Chronic Lymphocytic Leukemia
Primary: Overall Response — 8; 14; 19 Participants
Kidney Transplantation
Primary: Mean Percent Change in Glomerular Filtration Rate From Baseline to Month 12 — 59.5; 58.8; 24.4; 5.2 percent change — p=0.012
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 9.4 Weeks
Arthritis, Gouty
Primary: Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity — 3.03; 2.73; 2.84; 2.83 Scores on a scale
Severe Respiratory Syncytial Virus Infection
Primary: Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Infection, Serious Arrhythmia and/or Death — 303; 349 participants
Alzheimer's Disease
Primary: Change in Mean Computer-based Cognitive Assessment (CogState) Composite Score at Week 4 — -0.10; -0.07 Score on a scale — p=0.231
Psoriasis
Primary: Psoriasis Area and Severity Index (PASI) 75 Response Rate at Week 10 — 71 Percentage of participants
Photoaging
Primary: Change From Baseline in Overall Integrated Assessment of Photodamage at Week 24 — 6; 10 participants
Asthma
Primary: Exhaled Nitric Oxide — 67.0; 54.8 parts per billion (ppb) — p=<0.03
Adrenal Tumors
Primary: Increase in Catecholamine
Psoriasis
Primary: Number of Participants Who Achieve at Least 75% Improvement in Palmoplantar Psoriasis Activity Severity Index (PPPASI) After 3 Infusions. — 4 participants
Hepatitis B · Hepatitis A
Primary: Number of Subjects With Anti-hepatitis A (Anti-HAV) Antibody Concentrations Equal to or Above Cut-off Value — 25; 28; 23; 24 Participants
Obliterative Bronchiolitis
Primary: Per Cent Change of Forced Expiratory Volume in 1 Second (FEV1) After Bronchodilators — 14; 7 per cent positive change
Osteosarcoma · Medulloblastoma · Sarcoma, Ewing's
Primary: Percentage of Participants With Overall Tumor Response (Response Rate) — 0; 0; 0; 0 Percentage of Participants
Obesity · Overweight
Primary: Gestational Weight Gain — 10.3; 11.5 kg — p=<0.05